AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00034801
Drug: ziprasidone
RxNorm normalized name: Ziprasidone
DrugBank: Ziprasidone (DB00246)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04246359
Drug: Rituximab Biosimilar
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: To evaluate the short-term objective efficacy of HLX01 combined with Pegylated Interferon α-2b in patients with advanced idolent B-cell lymphoma.
Trial: NCT04246359
Drug: Pegylated Interferon α-2b
RxNorm normalized name: Pegylated proline interferon alpha-2b
DrugBank: Ropeginterferon alfa-2b (DB15119)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: To evaluate the short-term objective efficacy of HLX01 combined with Pegylated Interferon α-2b in patients with advanced idolent B-cell lymphoma.
Trial: NCT03165227
Drug: BI 685509
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taken orally
Trial: NCT00207077
Drug: Cetuximab + Erlotinib
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IV solution + tablet, IV+ oral, ERB 100 mg/m2, 200 mg/m2, 250 mg/m2 IV + Erl 150 mg tablet, ERB weekly/ Erl once daily, Until disease progression.
Trial: NCT00560599
Drug: mupirocin and chlorhexidine
RxNorm normalized name: Mupirocin
DrugBank: Mupirocin (DB00410)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mupirocin (Bactroban Nasal): twice a day for 7 days, apply one pea-sized amount of Bactroban Nasal ointment directly into one nostril and another pea-sized amount for the other nostril.~Chlorhexidine (Hibiclens): once a day for 14 days, rinse body with chlorhexidine.
Trial: NCT00560599
Drug: mupirocin, chlorhexidine, & household cleaning/disinfection
DrugBank: Mupirocin (DB00410)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mupirocin (Bactroban Nasal): twice a day for 7 days, apply one pea-sized amount of Bactroban Nasal ointment directly into one nostril and another pea-sized amount for the other nostril.~Chlorhexidine (Hibiclens): once a day for 14 days, rinse body with chlorhexidine.~Environmental cleaning with topical ethanol and laundering of clothes and linen.
Trial: NCT03306589
Drug: Saline Solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.9 percent sodium chloride will be administered via IV route to all subjects at a rate of 250 mL/hour for 4 hours prior to dosing with LPS and 8 hours after dosing with LPS.
Trial: NCT01693640
Drug: Abatacept
RxNorm normalized name: Abatacept
DrugBank: Abatacept (DB01281)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Weekly injections with Abatacept 125 mg over 6 months
Trial: NCT03854578
Drug: BI 1358894
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Film-coated tablet
Trial: NCT03854578
Drug: Citalopram
RxNorm normalized name: Citalopram
DrugBank: Citalopram (DB00215)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Film-coated tablet
Trial: NCT02702076
Drug: Apomorphine
RxNorm normalized name: Apomorphine
DrugBank: Apomorphine (DB00714)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuous subcutaneous infusion of apomorphine during waking day
Trial: NCT00372658
Drug: 1% Lidocaine intracervical injection
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00672464
Drug: Olanzapine
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olanzapine zydis 15 mg QHS for 28 days
Trial: NCT00672464
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin capsules will be started at 500 mg twice a day (before breakfast and before dinner) for days 1-3, then 500 mg before breakfast and 1000 mg before dinner for days 4-7, and then 1000 mg twice a day thereafter.
Trial: NCT03249259
Drug: Choline alfoscerate
RxNorm normalized name: Choline Alfoscerate
DrugBank: Choline alfoscerate (DB04660)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment duration is 6 months and can be extended to 12 months with participant's agreement.
Trial: NCT03466216
Drug: AlphaMedix
RxNorm normalized name: Alphamedix
DrugBank: Dotamtate Pb-212 (DB17312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: There is only a single treatment intervention.
Trial: NCT00267202
Drug: Omalizumab
RxNorm normalized name: Omalizumab
DrugBank: Omalizumab (DB00043)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Doses of omalizumab were administered subcutaneously every 2 to 4 weeks according to the US product label, depending on the patient's body weight and baseline serum IgE.
Trial: NCT01572012
Drug: Ondansetron
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ondansetron solution 4 mg single administration
Trial: NCT01572012
Drug: Ondansetron + Hylenex
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ondansetron solution (4 mg) single administration + Hylenex recombinant (150 U) single administration
Trial: NCT01572012
Drug: Zofran ODT
RxNorm normalized name: Zofran ODT
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zofran ODT (8 mg) single administration
Trial: NCT01572012
Drug: Ondansetron solution
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ondansetron solution (4 mg) single administration
Trial: NCT01766466
Drug: cangrelor
RxNorm normalized name: Cangrelor
DrugBank: Cangrelor (DB06441)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Open-label cangrelor IV bolus (30 µg/kg), followed by an infusion of 4 µg/kg/min for two hours.
Trial: NCT01766466
Drug: Ticagrelor
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ticagrelor 180mg dose: administered 0.5 h or 1.5h after the initiation of cangrelor infusion~Ticagrelor 90mg: 6 or 7 doses (depending on study arm) taken every 12 hours post cangrelor infusion.
Trial: NCT01014442
Drug: mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1.5 g PO BID from Days 2 to 30 post-transplantation, 1 g PO BID Days 31 to 90 post-transplantation
Trial: NCT02479399
Drug: ipragliflozin
RxNorm normalized name: ipragliflozin
DrugBank: Ipragliflozin (DB11698)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Tablets
Trial: NCT01136759
Drug: Tenofovir 1% gel
DrugBank: Tenofovir (DB14126)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One applicator of tenofovir 1% gel administered vaginally for 7 consecutive days
Trial: NCT00097916
Drug: memantine HCl
RxNorm normalized name: memantine HCl
DrugBank: Memantine (DB01043)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03765554
Drug: PF-06700841 Immediate release tablets
RxNorm normalized name: PF-06700841
DrugBank: PF-06700841 (DB15003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Small molecule tablets in immediate release form
Trial: NCT03765554
Drug: PF-06700841 Modified release tablets
RxNorm normalized name: PF-06700841
DrugBank: PF-06700841 (DB15003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Small molecule tablets in modified release form
Trial: NCT02939807
Drug: ABC294640
RxNorm normalized name: ABC294640
DrugBank: Opaganib (DB12764)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABC294640 500 mg orally twice daily (approximately 12 hours apart) continuously.~ABC294640 will be dosed under fasting conditions (at least 1 hour before or 2 hours after eating). A cycle is defined as 28 days.
Trial: NCT03164304
Drug: Magnesium Sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: intravenous
Trial: NCT00265109
Drug: Levetiracetam
RxNorm normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: The initial levetiracetam dose will be 250 mg/day, which will be increased to 250 mg BID after 1 week. The dose will then be increased by 500 mg/day each week (given in BID dosing) to a maximum of 3,000 mg/day. The dose will be raised more slowly or the maximum dose will not be reached if response occurs at a lower dose or side effects are problematic. Subjects who are unable to tolerate at least 500 mg a day of levetiracetam will be withdrawn from the study.
Trial: NCT03363841
Drug: SCY-078
RxNorm normalized name: SCY-635
DrugBank: SCY-635 (DB12451)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral SCY-078
Trial: NCT02102646
Drug: Triptorelin
RxNorm normalized name: triptorelin
DrugBank: Triptorelin (DB06825)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Androgen deprivation therapy by Pamorelin 22,5mg/24 weeks administered intramuscularly.
Trial: NCT00017212
Drug: exatecan mesylate
RxNorm normalized name: mesylate
DrugBank: Exatecan (DB12185)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01076478
Drug: Cilostazol
RxNorm normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg, 200mg tablet Cilostazol
Trial: NCT01531049
Drug: varenicline
RxNorm normalized name: Varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: days 1.-3 0,5mgx1/day, days 4.-7 0,5mgx2/day, day 8 to the 12weeks 1mgx2 /day
Trial: NCT01531049
Drug: Nicotine cutaneous patch 15mg/16h
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One patch for 16hours/day and duration of 8 weeks.
Trial: NCT01531049
Drug: Nicotine cutaneous patch 10mg/16h
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One patch 16hours/day and duration of 8 weeks
Trial: NCT00724594
Drug: N-acetylcysteine
RxNorm normalized name: N-acetylcysteine
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NAC (100 mg/kg/dose) was given intravenously to mothers within 4 hours of diagnosis of chorioamnionitis, and every 6 hours until delivery. NAC was given to preterm (12.5 mg/kg/dose) and term infants (25 mg/kg/dose) every 12 hours for 5 doses after birth.
Trial: NCT00724594
Drug: Control
RxNorm normalized name: Control
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline was given in the same volume, at the same timing as NAC infusions
Trial: NCT04414150
Drug: SHR-1802
RxNorm normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This study will evaluate the preliminary safety, tolerability, pharmacokinetic characteristics and initial efficacy of SHR-1802 The goal is to establish the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of sequential escalating doses of SHR-1802 when administered to patients with locally advanced/ unresectable or metastatic malignant tumours that are refractory to available therapy or for which no standard therapy is available.
Trial: NCT02357654
Drug: GnRH
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: single shot of GnRH agonist
Trial: NCT00808665
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will be given 0.7 mcg/kg/hr of dexmedetomidine over the first hour of surgery, followed by continuous infusion of 0.5 mcg/kg/hr of dexmedetomidine for the next 2 hours of surgery. Dexmedetomidine dose will be reduced to 0.2 mcg/kg/hr for the duration of the procedure and continued at that rate for four hours postoperatively. Patients in the placebo arm will receive an equal per-kg IV volume of 0.9% Sodium Chloride over the same periods. Drug administration will be controlled for both arms of the study using a continuous infusion pump.
Trial: NCT00374920
Drug: MEM 1003
RxNorm normalized name: MEM 1003
DrugBank: MEM 1003 (DB05547)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03557294
Drug: 1.0mg Varenicline b.i.d.
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Varenicline is classified as a selective nicotine receptor partial agonist (SNRPA) that works both to stimulate the nicotine receptor and block smoking reward at the α4β2 nicotinic receptor subtype.
Trial: NCT03557294
Drug: 0.5mg Varenicline b.i.d.
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Varenicline is classified as a selective nicotine receptor partial agonist (SNRPA) that works both to stimulate the nicotine receptor and block smoking reward at the α4β2 nicotinic receptor subtype.
Trial: NCT03557294
Drug: 0.0mg placebo Varenicline b.i.d.
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Product that looks like active varenicline, but contains no active ingredient
Trial: NCT01697631
Drug: biphasic insulin aspart 30
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administrated subcutaneously (s.c., under the skin) at breakfast and evening main meals
Trial: NCT01697631
Drug: insulin aspart
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administrated subcutaneously (s.c., under the skin) before lunch
Trial: NCT04225026
Drug: GC4419 (avasopasem manganese)
RxNorm normalized name: Avasopasem manganese
DrugBank: Avasopasem manganese (DB16354)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90 mg, by 60-minute IV infusion, prior to each fraction of RT
Trial: NCT03748628
Drug: EDP-305
RxNorm normalized name: INDIGOFERA TINCTORIA LEAF 0.999 in 100 g TOPICAL POWDER [EDP INDIGO]
DrugBank: Indigofera tinctoria leaf (DB14314)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[14C\]EDP-305
Trial: NCT02058849
Drug: Beetroot
RxNorm normalized name: Beetroot
DrugBank: Beet (DB10640)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10g Beetroot powder mixed with 4-8 oz.
Trial: NCT04090203
Drug: Boiled Peanut Powder
DrugBank: Peanut (DB10553)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Immunotherapy will be administered utilizing a powder derived from boiled peanuts. Treatment will begin with an initial escalation day in which dosing is begun at 0.1 mg peanut protein and escalated to a final dose of 6 mg peanut protein. Doses are ingested orally. The subjects will continue daily oral ingestion of doses at home and return for updosing every 2 weeks to a final maintenance dose of 300 mg peanut protein. The subjects will continue daily oral ingestion of the peanut product for a minimum duration of 28 days before undergoing exit DBPCFC. At the conclusion of the study, patients will be offered continued maintenance therapy off study in line with current specialty standards.
Trial: NCT00746681
Drug: Tolterodine & Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tolterodine SR Oral, 2mg, once daily for 4 weeks Pregabalin, Oral, 75 mg, twice daily for 4 weeks
Trial: NCT00746681
Drug: Tolterodine
RxNorm normalized name: Tolterodine
DrugBank: Tolterodine (DB01036)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tolterodine SR, Oral, 4 mg, once daily for 4 weeks
Trial: NCT00746681
Drug: Tolterodine & Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tolterodine SR Oral, 4mg, once daily for 4 weeks Pregabalin, Oral, 150 mg, twice daily for 4 weeks
Trial: NCT00746681
Drug: Pregabalin
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pregabalin, Oral, 150 mg twice daily for 4 weeks
Trial: NCT01578447
Drug: Intramuscular DMPA
RxNorm normalized name: DMPA
DrugBank: Zytron (DB11768)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular DMPA
Trial: NCT03153085
Drug: Ipilimumab
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 3 mg/kg ipilimumab (for a total of 4 intravenous infusions, each administered at 3-week intervals).
Trial: NCT03910634
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin (AUC 2), QW1, intravenous drip, repeat for 4 weeks
Trial: NCT01122238
Drug: Nicotine Patch
RxNorm normalized name: Nicotine Patch
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: If randomized to only the Nicotine Patch condition (and not the Nicotine Gum):~Participants randomized to this condition will receive a 6-week supply of 14 mg patches at the initial visit. Participant will be instructed to use one patch daily for 6 weeks.
Trial: NCT01122238
Drug: Nicotine Gum
RxNorm normalized name: Equate Nicotine Gum 4mg Starter Kit
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: If randomized to only the Nicotine Gum condition (and not the Nicotine Patch):~Participants randomized to this condition will receive a 6-week supply of 2 mg gum at the initial visit. Participants will be instructed to use 10 pieces of gum daily for 6 weeks.
Trial: NCT01122238
Drug: Nicotine Patch + Nicotine Gum
RxNorm normalized name: nicotine Chewing Gum
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: If randomized to both the Nicotine Patch and the Nicotine Gum conditions:~Participants randomized to this condition will receive a 6-week supply of 14 mg patches and a 6-week supply of 2 mg gum at the initial visit. Participant will be instructed to use one patch daily and to use 10 pieces of gum daily for 6 weeks.
Trial: NCT01312857
Drug: panitumumab
RxNorm normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: All patients receive HAI FUDR (0.12 mg/kg/day X kg X pump volume) / pump flow rate and Dexamethasone flat dose of 25 mg on days 1.~All patients receive CPT-11 (150 mg/m2 IV over 30 min to an hour), Leucovorin (400 mg/m2 IV, over 30 min to an hour) and 5FU (1000 mg/m2/day continuous infusion over two days) on days 15 and 29 Randomization to panitumumab 6 mg/kg day 15 and 29 Each cycle repeats every 36 days for a total of 6 cycles
Trial: NCT01312857
Drug: Randomization to No Panitumumab
RxNorm normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: All patients receive HAI FUDR (0.12 mg/kg/day X kg X pump volume) / pump flow rate and Dexamethasone flat dose of 25 mg on days 1.~All patients receive CPT-11 (150 mg/m2 IV over 30 min to an hour), Leucovorin (400 mg/m2 IV, over 30 min to an hour) and 5FU (1000 mg/m2/day continuous infusion over two days) on days 15 and 29 Randomization (to no panitumumab) Each cycle repeats every 36 days for a total of 6 cycles
Trial: NCT03449342
Drug: turoctocog alfa
RxNorm normalized name: Turoctocog alfa
DrugBank: Turoctocog alfa (DB09109)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Patients will receive standard prophylaxis treatment and treatment of bleeding episodes, according to label. Trial product will be administered as intravenous injections (i.v.)
Trial: NCT00779506
Drug: Quetiapine Fumarate XR
RxNorm normalized name: Quetiapine Fumarate
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral, once daily, flexible dose
Trial: NCT03566290
Drug: GTx-024
RxNorm normalized name: toremifene
DrugBank: Toremifene (DB00539)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Study drug is an opaque, white to off-white, size 5, oval Softgel capsule containing the active ingredient GTx-024. Subjects will be required to take one 3 mg Softgel capsule per day.
Trial: NCT03448406
Drug: Empagliflozin
RxNorm normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Film-coated tablet
Trial: NCT02911311
Drug: intravitreal injection of conbercept
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
DrugBank: Conbercept (DB12460)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: conbercept is an anti-VEGF agent and is approved by the Food and Drug Administration for wet age-related macular degeneration
Trial: NCT00383292
Drug: tasisulam
RxNorm normalized name: Tasisulam
DrugBank: Tasisulam (DB11941)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tasisulam dose is dependent on participant's height, weight, and gender and is adjusted to target a specific Cmax based on participant laboratory parameters. Tasisulam is administered intravenously every 28 days until disease progression or other criteria for participant discontinuation are met.
Trial: NCT01478490
Drug: mirabegron
RxNorm normalized name: Mirabegron
DrugBank: Mirabegron (DB08893)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT01478490
Drug: metoprolol
RxNorm normalized name: Metoprolol
DrugBank: Metoprolol (DB00264)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT01473108
Drug: Finerenone (BAY 94-8862) PEG solution
RxNorm normalized name: Finerenone
DrugBank: Finerenone (DB16165)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 2.5, 5, 10, 20 mg polyethylene glycol (PEG) solution of BAY 94-8862
Trial: NCT01473108
Drug: Finerenone (BAY 94-8862) immediate release tablet
RxNorm normalized name: Finerenone
DrugBank: Finerenone (DB16165)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 20 mg BAY 94-8862 administered as 2 x 10 mg IR tablets
Trial: NCT01748292
Drug: 0.5 mg ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subject will receive drug (ranibizumab) via intravitreal injections (IVT) at every visit.
Trial: NCT03905018
Drug: Tadalafil 20 MG
RxNorm normalized name: tadalafil 20 MG
DrugBank: Tadalafil (DB00820)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: tadalafil 20 mg orally ,after a single administration
Trial: NCT04232722
Drug: Arsenicals
RxNorm normalized name: arsenic
DrugBank: Arsenic trioxide (DB01169)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: As4 S4
Trial: NCT01459211
Drug: Lenalidomide & Dexamethasone
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subjects with relapsed or refractory CLL will receive twelve 28-day cycles of treatment. Each cycle will consist of:~1. Oral Dexamethasone (20mg daily, days 1-4),~2. Oral Lenalidomide on days 1-28 of each cycle, starting at 5mg per day in cycle 1 in patients with creatinine clearance ≥ 60ml/min calculated by Cockcroft-Gault. The dose will be increased to 10mg per day with cycles 2-12 unless there is evidence of disease progression or unacceptable drug toxicity